Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03740009 · ClinicalTrials.gov registry record · Phase 4
Effects of a Tissue Selective Estrogen Complex (TSEC) on Depression and the Neural Reward System in the Perimenopause"
A Phase 4 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT03740009 is a Phase 4 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 20 participants.
The verdict
NCT03740009, a Phase 4 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
Using neuroimaging, the investigator will study the effects of estrogen on mood and brain function in perimenopausal women with depression.
Interventions
- DRUG Bazedoxifene/Conjugated Estrogen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-01-02 |
| Est. Completion | 2021-05-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03740009
The ClinicalTrials.gov registry entry for NCT03740009 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bazedoxifene/Conjugated Estrogen is the first listed.
NCT03740009 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03740009 about?
NCT03740009 is a clinical study titled "Effects of a Tissue Selective Estrogen Complex (TSEC) on Depression and the Neural Reward System in the Perimenopause"". Using neuroimaging, the investigator will study the effects of estrogen on mood and brain function in perimenopausal women with depression.
What is the current status of trial NCT03740009?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2019-01-02. Estimated completion is 2021-05-17.
What interventions are being tested in trial NCT03740009?
The interventions under investigation include: Bazedoxifene/Conjugated Estrogen (DRUG).
Who is sponsoring clinical trial NCT03740009?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.